Clinical trial details

Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without Tremelimumab in MSS and MSI colorectal and endometrial tumors: the SERPENTINE clinical trial

Identifier

ESR 21-21165

Sponsor

VHIO - VALL D HEBRON INSTITUT D ONCOLOGIA

Principal Investigator

ELENA ELEZ FERNANDEZ

Service

Oncology

Study details

Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Immunotherapy
Phase: II
Randomization: Non-randomized

Molecular details

Biomarker: MSI pos; MSS
Biomarker criteria: Mandatory
Prescreening: Local
Additional study population requirements: Not applicable

Drug details

Arm A: Durvalumab
Arm B: Durvalumab AND Tremelimumab

Links

Clinical Trials GOV (NCT identifier): NCT06680739
EU Clinical Trials Register (eudraCT Identifier): 2021-004061-13